

# Management strategies for congenital isolated hydronephrosis and the natural course of the disease

Jiwon Jung<sup>1</sup> , Joo Hoon Lee<sup>1</sup> , Kun Suk Kim<sup>2</sup> , Sang Hun Song<sup>2</sup> , Dae Hyuk Moon<sup>3</sup> , Hee Mang Yoon<sup>4</sup> , Young Ah Cho<sup>4</sup> , Young Seo Park<sup>1</sup> 

<sup>1</sup>Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>2</sup>Department of Pediatric Urology, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>3</sup>Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

<sup>4</sup>Department of Radiology, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea

Congenital isolated hydronephrosis encompasses a spectrum of physiologic states that spontaneously resolve and pathologic obstruction that necessitates surgical intervention. Distinguishing patients whose condition will resolve, those who will require stringent follow-up, and those who will eventually need surgical intervention present a challenge to clinicians, particularly because no unified guidelines for assessment and follow-up have been established. The recognition of the natural course and prognosis of hydronephrosis and a comprehensive understanding of the currently proposed consensus guidelines may aid in multidisciplinary treatment and in providing proper counseling to caregivers. In this review, we aimed to summarize the literature on the grading systems and management strategies for congenital isolated hydronephrosis.

**Keywords:** Congenital; Hydronephrosis; Ureteral obstruction

## Introduction

Hydronephrosis refers to dilatation of the renal collecting system due to a build-up of urine resulting from drainage problems. Congenital hydronephrosis occurs in up to 1%–5% of all pregnancies [1,2]. More than half of the cases are transient and physiologic, whereas other cases are caused by disorders of the ureteropelvic junction (UPJ) including intrinsic stenosis (10%–30%), vesicoureteral reflux (VUR; 10%–30%), and congenital anomalies leading to secondary dilatation of the urinary tract [1,3,4]. To date, studies have shown that low-grade isolated hydronephrosis usually resolves during the first few years of life [5,6], whereas high-grade hydronephrosis requires interven-

tion to prevent the progression of obstruction or deterioration of renal function [7].

Distinguishing children who require follow-up or intervention, determining the possibility of resolution and the time to resolution, deciding about performing pyeloplasty to relieve the obstruction and determining the timing of the procedure, and preserving the patient's renal function are crucial issues for both clinicians and family members. To stratify the risk of early surgical intervention or the possibility of resolution, attempts have been made to create a unified grading system for urinary tract dilatation that can be used during the prenatal or postnatal period; however, no definitive consensus guidelines have been established to date [8].

Received: March 17, 2022; Accepted: April 1, 2022

### Correspondence to

Young Seo Park  
Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea  
E-mail: yspark@amc.seoul.kr

© 2022 Korean Society of Pediatric Nephrology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

In this review, we aimed to summarize the literature (to date) on the proposed grading systems and management strategies for congenital isolated hydronephrosis, as well as to describe the natural history.

## Detection and classification–grading systems

Currently, no standardized protocol exists for defining, classifying, and grading congenital hydronephrosis. Different terminologies with overlapping meanings are used to describe the status of dilatation (e.g., pelviectasia, pelviectasis, hydronephrosis, and urinary tract dilatation), and different clinicians from different subspecialties (e.g., pediatric urology, pediatric radiology, pediatric nephrology, and obstetrics) may use the terms to refer to different conditions [9,10]. Consequently, several grading systems have been developed, leading to the use of various nomenclatures and causing a misunderstanding between the radiologist and the clinician [11]. In this context, we will review the most widely used and the recently proposed grading systems aimed at providing a unified classification during the perinatal period, including their validation in the literature.





### Society for Fetal Urology classification

In 1993, the Society for Fetal Urology (SFU) proposed a 5-point numeric grading system (0–IV) based on the postnatal appearance of the renal pelvis, calyces, and renal parenchyma on ultrasonography (USG) images (Fig. 1) [1,6,12]. The SFU classification remains the most widely used grading system owing to its intuitiveness and ease of use, especially in cases of isolated hydronephrosis. However, interobserver and intraobserver

variabilities exist owing to the nature of morphologic classification. Furthermore, since it was not originally developed for use in antenatal evaluation, it has not been widely adopted in subspecialties other than pediatric urology radiology (e.g., obstetrics and neonatology).

### Grading based on the anteroposterior pelvic diameter

Anteroposterior pelvic diameter (APD) measurement, obtained from a transverse section of the renal hilum, is also widely used by itself or in conjunction with SFU grading. APD is an objective quantitative parameter widely used as a predictor of pathology and outcome, as well as of the resolution of the condition or the need for an intervention [1,8,13]. However, it also has limitations. Because APD measurement does not provide descriptive details of the renal parenchyma, calyces, ureter, and lower urinary tract, it does not accurately reflect the degree of hydronephrosis according to different renal pelvic configurations. Some studies argue that there is no threshold separating nonobstructive from obstructive dilatation of the kidney because renal dilatation is affected by many factors (e.g., hydration status, bladder filling, position, and respiration of the patient) giving its dynamic character [11,14]. Because of the advantages and disadvantages of both grading systems, SFU grading and APD measurement are commonly used together complementarily in clinical practice. As the authors have previously demonstrated, in cases showing a discrepancy between morphologic classification and APD measurement (i.e., higher grade in the SFU classification than that based on APD measurement), the resolution time should be predicted using the APD measurement rather than the SFU grade [15]. This is because normalization of morphology occurs before improvement in the APD measurements.

| SFU grade 0   | SFU grade I   | SFU grade II  | SFU grade III  | SFU grade IV  |
|---|---|---|--|---|
| Normal, no splitting  | Urine in the pelvis barely splits the sinus   | Urine fills the pelvis, major calyces dilated                                       | Uniformly dilated minor calyces, parenchyma preserved                                | Parenchymal compromise with thinning  |
|  |  |  |  |  |

**Fig. 1.** Society for Fetal Urology (SFU) hydronephrosis grading system. The SFU grading system is based on the degree of renal-pelvic and calyceal dilatation seen on renal ultrasonography images and the integrity of the renal parenchyma [12].

**Urinary tract dilation classification system**

The urinary tract dilation (UTD) classification system was developed in 2014 as a collaborative effort among eight different medical and surgical societies (American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Pediatric Nephrology, SFU, Society for Maternal-Fetal Medicine, Society for Pediatric Urology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound) in an attempt to establish a standardized and simplified description of hydronephrosis that can be consistently applied across specialties for prenatal and postnatal evaluation and management [8,16]. This classification includes parameters such as the APD of the renal pelvis (normal, <10 mm), presence of central and peripheral calyceal dilatation, renal parenchymal abnormalities, ureteral abnormalities, and bladder abnormalities in two antenatal (UTD-A1 and UTD-A2) and three postnatal (UTD-P1, UTD-P2, and UTD-P3) categories (Fig. 2). This system is intended to stratify the risk of postnatal uropathies and the clinical outcomes and to conduct a cost-effective evaluation in high-risk patients rather than being a mere descriptive grading system [8,17]. However, the system may also cause confusion because the classification suggests the general term “urinary tract dilatation” to indicate all types of ureteral and kidney dilatation, including UPJ obstruction (UPJO), ureterovesical junction-type

hydroureteronephrosis, VUR, bladder pathologies, and posterior urethral valve formation. Its additional limitations include interrater discrepancy in the assessment of calyceal dilatation, the wide range encompassed by the UTD-P3 grade, and the complexity and time-consuming nature of its application in real clinical practice [11]. Nonetheless, some studies have validated the usefulness of the UTD grading system in predicting the need for surgical intervention or predicting urinary tract infection by showing a relationship between UTD grade and clinical outcomes [17-24].

**Onen grading system**

The Onen system was developed in 2007 for the assessment of prenatal and postnatal hydronephrosis with UPJ pathology, with emphasis on the quality of the renal parenchyma, and was updated in 2016 [11,25]. It is based on nonsubjective parameters (presence of dilatation of the pelvicalyceal system and quality of the renal parenchyma based on exact criteria) (Fig. 3). Although the system is not widely used because of low recognition by practitioners, a few groups have recently reported its low subjectivity with a decreased interobserver agreement in Onen grades 2 to 3 [26,27].

Among the aforementioned grading systems, the SFU classification of congenital hydronephrosis seems to remain the

|  | UTD-P1<br>(low risk)                                      | UTD-P2<br>(intermediate risk)                        | UTD-P3<br>(high risk) |
|--|---|--|-----------------------|
| APD  | 10 to <15 mm  | ≥15 mm   | ≥10 mm                |
|  | <b>OR</b>   | <b>OR</b>  | <b>OR</b>             |
| Calyces  | Central dilatation<br>(pelviectasis,<br>pelvicaliectasis) | Peripheral dilatation                                | Any dilatation        |
|  |   | <b>OR</b>  |                       |
| Ureter   |   | ≥4 mm<br>(with APD ≥10 mm or<br>calyceal dilatation) |                       |
|  |   |  | <b>AND</b>            |
| Parenchymal abnormality,<br>bladder abnormality or prenatal<br>oligohydramnios |   |  | Yes                   |

**Fig. 2.** Urinary tract dilation (UTD) classification system (postnatal categories). Although the UTD classification system has two antenatal categories (UTD-A1 and UTD-A2-3) and three postnatal categories (UTD-P1, UTD-P2, and UTD-P3) [8,16], only the postnatal categories (>48 hours) are presented here. APD, anteroposterior pelvic diameter. Adapted from Nguyen et al. [16] with permission from Springer.

| Onen-1  | Onen-2  | Onen-3  | Onen-4  |
|---|---|---|---|
| Only renal pelvic dilatation<br>(APD not important)                               | Pelvic+calyceal dilatation<br>(APD not important,<br>renal parenchyma normal)     | Medulla short and thin,<br>postnatal 3–7 mm<br>(APD not important,<br>corticomedullary<br>differentiation normal) | Severe parenchymal loss<br>with thin cortex, postnatal <3 mm<br>no medulla<br>(APD not important, no<br>corticomedullary differentiation) |
|  |  |                                 |    |

**Fig. 3.** Onen grading system. The diagram summarizes the Onen grading system, reflecting the 2016 update on grades 3 and 4 [26]. APD, anteroposterior pelvic diameter.

most widely used classification system by clinicians owing to familiarity and established practice patterns, followed by APD measurement and the UTD system [17,28,29].

### Risk-based management and follow-up plan after birth

As previously mentioned, no universal guideline exists on the frequency and timing of USG examination and the required duration of follow-up. In addition, heterogeneity in clinical management exists among pediatric radiologists, pediatric urologists, and maternal-fetal obstetricians, partly because of the lack of prospective studies and different practices across different centers [10]. This section will cover the postnatal management of congenital hydronephrosis according to the current literature in the context of clinical decision-making (Fig. 4).


For unilateral hydronephrosis, postnatal evaluation should begin within the first week (after the second day, usually from the fifth to seventh days, to ensure adequate hydration) of life using renal USG. For bilateral hydronephrosis, early postnatal imaging is recommended. After the initial evaluation, follow-up and management are stratified according to severity, as assessed using the aforementioned grading systems.

In cases of known prenatal hydronephrosis that show normalization on the first postnatal USG, the follow-up may be terminated. However, 15% to 45% of patients with normalized initial USG results show abnormal USG results on follow-up, suggesting the need for a second USG examination at 1 to 6 months of age (varying among studies) despite normal findings on the first USG [1,14,30,31].

In the case of mild hydronephrosis (generally grade I and

unilateral grade II in SFU grading and UTD-P1), observational studies anecdotally recommend less aggressive imaging follow-up [14,31], or no further follow-up [32], owing to the nature of spontaneous resolution during the first 2 to 3 years [15,19,33]. Irrespective of the suggestions, an APD of approximately 10 to 20 mm (cutoff value may vary among studies) can be managed conservatively [14,15,34]. Follow-up evaluations using USG after 3 to 6 months for the first year, every 6 months until 3 years, and every 1 to 2 years thereafter (or according to the symptoms [flank pain, dysuria] articulated by the patient) are usually recommended [8,14,31]. Although extremely rare, late worsening after spontaneous resolution can occur in some patients (1%–5%) in a few months (up to 5–6 years) [35], even in patients with mild congenital hydronephrosis [1,33,36]. Clinicians should be aware of this possibility and educate the patients and caregivers about the possible need for follow-up imaging in intervals (varying from 1 to 6–12 months among studies) after resolution or when symptoms such as abdominal pain and urinary symptoms appear [1,8,14,36–38].

For moderate hydronephrosis with an intermediate risk of progression (bilateral SFU grade II, SFU grade III, and UTD-P2), a second USG examination is recommended in the first month and every 1 to 3 months thereafter, during the first year, depending on the stability of the patient's condition. For the next 2 years, follow-up every 6 months is recommended. Annual follow-up or follow-up according to the symptoms (flank pain and dysuria) articulated by the toddler until 6 years is also recommended [8,14,31]. Diuretic renal scan (DRS), which can be performed from 6 to 8 weeks of age, is the most commonly used modality for assessing the presence of upper urinary tract obstruction in infants. It is usually recommended when two



**Fig. 4.** Suggested follow-up and management strategies for congenital isolated hydronephrosis. The diagram summarizes the proposed guidelines from the literature. USG, ultrasonography; SFU, Society for Fetal Urology; UTD, urinary tract dilatation; DRS, diuretic renal scan; VCUG, voiding cystourethrography; prn, pro re nata.

renal USG examinations, during at least 3 months, show no improvement or suggest the aggravation of moderate hydronephrosis. The indications for voiding cystourethrography (VCUG) include bilateral hydronephrosis, ureteral dilatation, abnormal renal echogenicity, and abnormal appearance of the bladder, which are suggestive of lower urinary tract disease (e.g., posterior urethral valve or VUR) [5]. However, the decision to recommend DRS or VCUG is dependent on the clinician's discretion because less invasiveness and cost-effectiveness in evaluation are recently being emphasized, supported by the fact that most patients remain asymptomatic without severe pathology [8,31]. Duong et al. [39] suggested that DRS should only be performed in patients with APD  $\geq 30$  mm, major calyceal dilatation ( $>10$  mm), or renal parenchymal thinning and emphasized the need for more conservative management among patients with mild-to-moderate hydronephrosis.

For severe, high-risk hydronephrosis (SFU grade IV, UTD-P3), USG examination should be repeated at 1 month, followed by DRS at age 6 to 8 weeks [8,31]. The possibility of a later follow-up using USG examination and DRS/VCUG depends on the results of second USG with DRS, and the plans for surgery. The index of obstructive uropathy (UPJO) and the indications for surgical

intervention will be addressed later.

### Natural course of isolated hydronephrosis

According to existing studies,  $>50\%$  to  $70\%$  of all cases of isolated hydronephrosis resolve regardless of the grade [5,6,15,40]. The resolution rate differs according to the baseline severity of hydronephrosis. Prior studies on low-grade hydronephrosis (SFU grades I–II and APD  $<10$ – $20$  mm) showed resolution or improvement in  $56.0\%$  to  $97.4\%$  of the cases, implying a benign condition [6,41,42]. Elmaci and Donmez [13] evaluated the congenital hydronephrosis's time to resolution in patients with APD  $<20$  mm; those with APD  $<10$  mm showed complete resolution in a median of 5 months, whereas those with an APD of 10 to 20 mm showed complete resolution in a median of 11 months. In addition, cumulative resolution rates were reported by several prospective and retrospective studies. In a prospective study, Braga et al. [19] reported the cumulative resolution rate at 3 years for each grade in the SFU and UTD systems (98% for SFU I, 87% for SFU II, 76% for SFU III, and 56% for SFU IV; 90% for UTD-P1, 81% for UTD-P2, and 71% for UTD-P3). In addition, the authors previously reported the cumulative resolution rates

of isolated hydronephrosis at 2 years in a retrospective study (81.7%, 65.6%, 37.6%, and 5.2% for SFU grades I, II, III, and IV, respectively) [15]. Among cases of high-grade hydronephrosis associated with UPJ stenosis, approximately 27% show resolution, >50% remain stable, and the rest progress with possible renal function deterioration [3]. Surgical intervention has been required in approximately 25% of all cases, ranging from 5% to 50% depending on the study [1,15,43-46]. Therefore, after at least 2 to 3 years of watchful observation and evaluation, termination of follow-up may be possible since the outcome would be determined within these years.

## Prediction and decision of intervention

Disagreements about the definition of obstruction and the indications and timing of surgery in hydronephrosis due to UPJO remain. The appearance of symptoms of UPJO, such as pain and urinary tract infection, is indicative of the need for surgery. A differential renal function of <40% with impaired drainage ( $T_{1/2}$  >20 minutes) on DRS or a >10% deterioration of renal function on a serial renal scan is also generally considered a surgical indication [6,31,38,47].

Additional studies have presented the predictors of surgery and their corresponding cutoff values, including initial postnatal APD, cortical tissue transit time on DRS, renal pyramidal thickness, and renal parenchyma-to-hydronephrosis area ratio (PHAR) [34,47-51].

### Initial postnatal APD

Postnatal APD has been widely used as an index for evaluating and anticipating the presence of obstruction, with advantages of wide availability and absence of radiation exposure. In clinical practice, sequential changes in APD are mainly used to determine management plans. Although no absolute cutoff value of APD for performing pyeloplasty has been defined, several studies suggested different APD values, ranging from 15 to 30 mm, as significant predictors of surgical intervention [8,34,37,50,52]. Arora et al. [47] performed a prospective multivariate analysis and showed that an APD of up to 24 mm in the first week after birth can predict the need for surgical intervention (sensitivity, 73.1%; specificity, 88.0%). The prospective cohort studies of Coelho et al. [37] and Dias et al. [34] suggested an APD of >15 and 18 mm as the cutoff value, respectively.

### Delayed tissue transit time in $^{99m}\text{Tc}$ -mercaptoacetyltriglycine DRS

Some recent studies have shown that delayed tissue transit time, which is defined as an absence of activity in the subcortical structures or in the pelvis on a  $^{99m}\text{Tc}$ -mercaptoacetyltriglycine (MAG3) DRS within 3 or 8 minutes of tracer injection, can predict deterioration of UPJO in pediatric populations [51,53-55]. Song et al. [56] proposed that delayed tissue transit time on  $^{99m}\text{Tc}$ -MAG3 DRS is a significant predictor of renal function improvement after pyeloplasty in patients with UPJO. Therefore, they suggested that delayed tissue transit time should be considered a candidate predictor of immediate pyeloplasty and decreased differential renal function.

### Renal pyramidal thickness

The renal pyramid is the first portion of renal parenchyma that becomes affected in high-grade hydronephrosis. The parenchymal thickness changes with age, making its clinical application difficult in a growing child. In contrast, the renal pyramid is a part of the parenchyma that grows slowly and shows only small changes in the first 9 years of life; thus, it is a feasible parameter for evaluation and comparison between serial USG images [57]. Pyramidal thickness measurement was not previously performed in patients with hydronephrosis until Hodhod et al. [48] recently measured pyramidal thickness in the supine position in the middle third of the sagittal plane. In their study, multivariate analysis showed that a renal pyramidal thickness of  $\leq 3$  mm (sensitivity, 98.1%; specificity, 89.7%) predicted the need for surgical intervention.

### Renal PHAR

Some studies have attempted to simultaneously measure the renal parenchymal volume and the grade of hydronephrosis using USG (without a renal scan) as a surrogate of renal function in patients with hydronephrosis [49,58]. In this regard, Rickard et al. [49] showed that the renal PHAR predicted the need for surgery (cutoff value, <0.5) in high-grade hydronephrosis (area under the receiver operating characteristic curve, 0.816;  $P < 0.001$ ) more efficiently than the APD measurement, SFU grade, and UTD classification.

## Risk of urinary tract infection

The existing studies commonly suggest that the risk of urinary tract infection increases with the degree of hydronephrosis.

Observational studies have shown that patients with moderate or severe hydronephrosis show an increased incidence (13.8%–40.0% for moderate-to-severe hydronephrosis vs. 4.1%–14.0% for mild hydronephrosis) of urinary tract infection [37,59–61]. Patients with hydronephrosis with obstructive drainage patterns on renal scans, without VUR, have a higher risk than those without obstructive patterns [61–63]. Furthermore, in terms of the benefits of antibiotic prophylaxis, different outcomes have been reported. Braga et al. [64,65] demonstrated a protective effect of antibiotic prophylaxis, especially in patients with high-grade hydronephrosis, in their systematic review and meta-analysis, whereas Estrada et al. [66] showed significant improvement in infection after prophylaxis even in patients with mild hydronephrosis. In clinical practice, the use of prophylactic antibiotics remains nonuniform owing to the absence of recommendations or guidelines from randomized control studies [67,68]. An ongoing randomized control trial on hydronephrosis with UPJO-like and non-refluxing megaureter by Braga et al. (Clinical Trials Registry no. NCT01140516) might aid in elucidating the effect of chemoprophylaxis. Therefore, clinicians are currently advised to decide whether they want to make use of antibiotics on a case-by-case basis while keeping in mind that high-grade hydronephrosis may confer an increased risk of urinary tract infection.

## Conclusions

Predicting the natural course of prenatally detected hydronephrosis has become possible with increasing knowledge and accumulated outcomes from cases treated with surgical intervention. Since no definite consensus exists about using a certain grading system in clinical practice, a practical, user-friendly system, combined with the use of an objective imaging modality that is generally accepted by multidisciplinary specialists, is needed. Furthermore, the establishment of the timing of the initial evaluation and follow-up intervals according to disease severity can aid in efficient management and help inform the caregivers and patients about the prognosis and follow-up plans.

## Conflicts of interest

Joo Hoon Lee is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of

interest relevant to this article were reported.

## Funding

None.

## Author contributions

Conceptualization: YSP, KSK  
 Data curation: JJ, JHL  
 Investigation: SHS  
 Methodology: HMY, YAC, DHM  
 Project administration: YSP  
 Visualization: SHS, HMY, YAC, DHM  
 Writing-original draft: JJ  
 Writing-review & editing: JJ, JHL, YSP, KSK  
 All authors read and approved the final manuscript.

## References

1. Nguyen HT, Herndon CD, Cooper C, Gatti J, Kirsch A, Kokorowski P, et al. The Society for Fetal Urology consensus statement on the evaluation and management of antenatal hydronephrosis. *J Pediatr Urol* 2010;6:212-31.
2. Choi HA, Lee DJ, Shin SM, Lee YK, Ko SY, Park SW. The prenatal and postnatal incidence of congenital anomalies of the kidneys and urinary tract (CAKUT) detected by ultrasound. *Child Kidney Dis* 2016;20:29-32.
3. Corbett HJ, McCarthy L. Hydronephrosis in children: pelviureteric junction dysfunction. *Surgery (Oxford)* 2013;31:135-9.
4. Kim MY, Im YJ, Hyun HS, Kang HG, Ha IS, Cheong HI, et al. A case of an ureteropelvic junction obstruction caused by a crossing vessel. *Child Kidney Dis* 2018;22:28-31.
5. Davenport MT, Merguerian PA, Koyle M. Antenatally diagnosed hydronephrosis: current postnatal management. *Pediatr Surg Int* 2013;29:207-14.
6. Sidhu G, Beyene J, Rosenblum ND. Outcome of isolated antenatal hydronephrosis: a systematic review and meta-analysis. *Pediatr Nephrol* 2006;21:218-24.
7. Sarhan OM, El Helaly A, Al Otay AH, Al Ghanbar M, Nakshabandi Z. Prenatally detected, unilateral, high-grade hydronephrosis: can we predict the natural history? *Can Urol Assoc J* 2018;12:E137-41.
8. Nguyen HT, Benson CB, Bromley B, Campbell JB, Chow J, Coleman B, et al. Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system). *J*

- Pediatr Urol 2014;10:982-98.
9. Chalmers DJ, Meyers ML, Brodie KE, Palmer C, Campbell JB. Inter-rater reliability of the APD, SFU and UTD grading systems in fetal sonography and MRI. *J Pediatr Urol* 2016;12:305.
  10. Zanetta VC, Rosman BM, Bromley B, Shipp TD, Chow JS, Campbell JB, et al. Variations in management of mild prenatal hydronephrosis among maternal-fetal medicine obstetricians, and pediatric urologists and radiologists. *J Urol* 2012;188:1935-9.
  11. Onen A. Grading of hydronephrosis: an ongoing challenge. *Front Pediatr* 2020;8:458.
  12. Fernbach SK, Maizels M, Conway JJ. Ultrasound grading of hydronephrosis: introduction to the system used by the Society for Fetal Urology. *Pediatr Radiol* 1993;23:478-80.
  13. Elmaci AM, Donmez MI. Time to resolution of isolated antenatal hydronephrosis with anteroposterior diameter  $\leq$  20 mm. *Eur J Pediatr* 2019;178:823-8.
  14. Timberlake MD, Herndon CD. Mild to moderate postnatal hydronephrosis: grading systems and management. *Nat Rev Urol* 2013;10:649-56.
  15. Jung J, Lee JH, Kim KS, Park YS. Utility of Society for Fetal Urology and anteroposterior pelvic diameter grading systems for estimating time to resolution of isolated hydronephrosis: a single center study. *J Urol* 2020;204:1048-53.
  16. Nguyen HT, Phelps A, Coley B, Darge K, Rhee A, Chow JS. 2021 update on the urinary tract dilation (UTD) classification system: clarifications, review of the literature, and practical suggestions. *Pediatr Radiol* 2022;52:740-51.
  17. Gray MC, Zilliox JM, Varda B, Herndon CD, Kurtz MP, Chow JS, et al. Assessment of urinary tract dilation grading amongst pediatric urologists. *J Pediatr Urol* 2020;16:457.
  18. Braga LH, McGrath M, Farrokhyar F, Jegatheeswaran K, Lorenzo AJ. Associations of initial Society for Fetal Urology grades and urinary tract dilatation risk groups with clinical outcomes in patients with isolated prenatal hydronephrosis. *J Urol* 2017;197(3 Pt 2):831-7.
  19. Braga LH, McGrath M, Farrokhyar F, Jegatheeswaran K, Lorenzo AJ. Society for Fetal Urology classification vs urinary tract dilation grading system for prognostication in prenatal hydronephrosis: a time to resolution analysis. *J Urol* 2018;199:1615-21.
  20. Cakici EK, Aydog O, Eroglu FK, Yazililas F, Ozlu SG, Uner C, et al. Value of renal pelvic diameter and urinary tract dilation classification in the prediction of urinary tract anomaly. *Pediatr Int* 2019;61:271-7.
  21. Hodhod A, Capolicchio JP, Jednak R, El-Sherif E, El-Doray Ael-A, El-Sherbiny M. Evaluation of urinary tract dilation classification system for grading postnatal hydronephrosis. *J Urol* 2016;195:725-30.
  22. Han M, Kim HG, Lee JD, Park SY, Sur YK. Conversion and reliability of two urological grading systems in infants: the Society for Fetal Urology and the urinary tract dilatation classifications system. *Pediatr Radiol* 2017;47:65-73.
  23. Rickard M, Easterbrook B, Kim S, Farrokhyar F, Stein N, Arora S, et al. Six of one, half a dozen of the other: a measure of multidisciplinary inter/intra-rater reliability of the Society for Fetal Urology and urinary tract dilation grading systems for hydronephrosis. *J Pediatr Urol* 2017;13:80.
  24. Kaspar CD, Lo M, Bunchman TE, Xiao N. The antenatal urinary tract dilation classification system accurately predicts severity of kidney and urinary tract abnormalities. *J Pediatr Urol* 2017;13:485.
  25. Onen A. An alternative grading system to refine the criteria for severity of hydronephrosis and optimal treatment guidelines in neonates with primary UPJ-type hydronephrosis. *J Pediatr Urol* 2007;3:200-5.
  26. Cho HY, Jung I, Kim YH, Kwon JY. Reliability of Society of Fetal Urology and Onen grading system in fetal hydronephrosis. *Obstet Gynecol Sci* 2019;62:87-92.
  27. Kim SY, Kim MJ, Yoon CS, Lee MS, Han KH, Lee MJ. Comparison of the reliability of two hydronephrosis grading systems: the Society for Foetal Urology grading system vs. the Onen grading system. *Clin Radiol* 2013;68:e484-90.
  28. Swenson DW, Darge K, Ziniel SI, Chow JS. Characterizing upper urinary tract dilation on ultrasound: a survey of North American pediatric radiologists' practices. *Pediatr Radiol* 2015;45:686-94.
  29. Suson KD, Preece J. Do current scientific reports of hydronephrosis make the grade? *J Pediatr Urol* 2020;16:597.
  30. Aksu N, Yavascan O, Kangin M, Kara OD, Aydin Y, Erdogan H, et al. Postnatal management of infants with antenatally detected hydronephrosis. *Pediatr Nephrol* 2005;20:1253-9.
  31. Yalcinkaya F, Ozcakar ZB. Management of antenatal hydronephrosis. *Pediatr Nephrol* 2020;35:2231-9.
  32. Djahangirian O, Young I, Dorgalli C, Bissaillon A, Tran NA, Walia A, et al. Safe discharge parameters for patients with isolated antenatal hydronephrosis. *J Pediatr Urol* 2018;14:321.
  33. Kohata E, Kimata T, Onuma C, Yamanouchi S, Tsuji S, Ohashi A, et al. Natural course of isolated mild congenital hydronephrosis: a 2-year prospective study at a single center in Japan. *Int J Urol* 2019;26:643-7.
  34. Dias CS, Silva JM, Pereira AK, Marino VS, Silva LA, Coelho AM, et al. Diagnostic accuracy of renal pelvic dilatation for detecting surgically managed ureteropelvic junction obstruction. *J Urol* 2013;190:661-6.
  35. Gatti JM, Broecker BH, Scherz HC, Perez-Brayfield MR, Kirsch AJ. Antenatal hydronephrosis with postnatal resolution: how long are

- postnatal studies warranted? *Urology* 2001;57:1178.
36. Matsui F, Shimada K, Matsumoto F, Takano S. Late recurrence of symptomatic hydronephrosis in patients with prenatally detected hydronephrosis and spontaneous improvement. *J Urol* 2008;180:322-5.
  37. Coelho GM, Bouzada MC, Pereira AK, Figueiredo BF, Leite MR, Oliveira DS, et al. Outcome of isolated antenatal hydronephrosis: a prospective cohort study. *Pediatr Nephrol* 2007;22:1727-34.
  38. Riccabona M, Avni FE, Blickman JG, Dacher JN, Darge K, Lobo ML, et al. Imaging recommendations in paediatric uroradiology: minutes of the ESPR workgroup session on urinary tract infection, fetal hydronephrosis, urinary tract ultrasonography and voiding cystourethrography, Barcelona, Spain, June 2007. *Pediatr Radiol* 2008;38:138-45.
  39. Duong HP, Piepsz A, Collier F, Khelif K, Christophe C, Cassart M, et al. Predicting the clinical outcome of antenatally detected unilateral pelviureteric junction stenosis. *Urology* 2013;82:691-6.
  40. Thomas DF. Prenatal diagnosis: what do we know of long-term outcomes? *J Pediatr Urol* 2010;6:204-11.
  41. Madden-Fuentes RJ, McNamara ER, Nseyo U, Wiener JS, Routh JC, Ross SS. Resolution rate of isolated low-grade hydronephrosis diagnosed within the first year of life. *J Pediatr Urol* 2014;10:639-44.
  42. Sarhan OM, Helaly AE, Al Otay A, Ghanbar MA, Nakshabandi Z. Isolated low grade prenatally detected unilateral hydronephrosis: do we need long term follow-up? *Int Braz J Urol* 2018;44:812-8.
  43. Thornburg LL, Pressman EK, Chelamkuri S, Hulbert W, Rabinowitz R, Mevorach R. Third trimester ultrasound of fetal pyelectasis: predictor for postnatal surgery. *J Pediatr Urol* 2008;4:51-4.
  44. Mesrobian HG, Mirza SP. Hydronephrosis: a view from the inside. *Pediatr Clin North Am* 2012;59:839-51.
  45. Chertin B, Pollack A, Koulikov D, Rabinowitz R, Hain D, Hadas-Halpren I, et al. Conservative treatment of ureteropelvic junction obstruction in children with antenatal diagnosis of hydronephrosis: lessons learned after 16 years of follow-up. *Eur Urol* 2006;49:734-9.
  46. Ismaili K, Hall M, Piepsz A, Alexander M, Schulman C, Avni FE. Insights into the pathogenesis and natural history of fetuses with renal pelvis dilatation. *Eur Urol* 2005;48:207-14.
  47. Arora S, Yadav P, Kumar M, Singh SK, Sureka SK, Mittal V, et al. Predictors for the need of surgery in antenatally detected hydronephrosis due to UPJ obstruction: a prospective multivariate analysis. *J Pediatr Urol* 2015;11:248.
  48. Hodhod A, Capolicchio JP, Jednak R, Eid H, El-Doray AE, El-Sherbiny M. Is the renal pyramidal thickness a good predictor for pyeloplasty in postnatal hydronephrosis? *J Pediatr Urol* 2018;14:277.
  49. Rickard M, Lorenzo AJ, Braga LH. Renal parenchyma to hydronephrosis area ratio (PHAR) as a predictor of future surgical intervention for infants with high-grade prenatal hydronephrosis. *Urology* 2017;101:85-9.
  50. Killi I, Avlan D, Taskinlar H, Kara PP, Apaydin FD, Delibas A, et al. Effective predictors for surgical decision in antenatal hydronephrosis: a prospective multiparameter analysis. *Turk J Urol* 2017;43:361-5.
  51. Lee JN, Kang JK, Jeong SY, Lee SM, Cho MH, Ha YS, et al. Predictive value of cortical transit time on MAG3 for surgery in antenatally detected unilateral hydronephrosis caused by ureteropelvic junction stenosis. *J Pediatr Urol* 2018;14:55.
  52. Longpre M, Nguan A, Macneily AE, Afshar K. Prediction of the outcome of antenatally diagnosed hydronephrosis: a multivariable analysis. *J Pediatr Urol* 2012;8:135-9.
  53. Harper L, Bourquard D, Grosos C, Abbo O, Ferdynus C, Michel JL, et al. Cortical transit time as a predictive marker of the need for surgery in children with pelvi-ureteric junction stenosis: preliminary study. *J Pediatr Urol* 2013;9(6 Pt B):1054-8.
  54. Piepsz A, Tondeur M, Nogarede C, Collier F, Ismaili K, Hall M, et al. Can severely impaired cortical transit predict which children with pelvi-ureteric junction stenosis detected antenatally might benefit from pyeloplasty? *Nucl Med Commun* 2011;32:199-205.
  55. Schlotmann A, Clorius JH, Clorius SN. Diuretic renography in hydronephrosis: renal tissue tracer transit predicts functional course and thereby need for surgery. *Eur J Nucl Med Mol Imaging* 2009;36:1665-73.
  56. Song SH, Park S, Chae SY, Moon DH, Park S, Kim KS. Predictors of renal functional improvement after pyeloplasty in ureteropelvic junction obstruction: clinical value of visually assessed renal tissue tracer transit in 99mTc-mercaptoacetyltriglycine renography. *Urology* 2017;108:149-54.
  57. Kadioglu A. Renal measurements, including length, parenchymal thickness, and medullary pyramid thickness, in healthy children: what are the normative ultrasound values? *AJR Am J Roentgenol* 2010;194:509-15.
  58. Rodriguez LV, Lock J, Kennedy WA, Shortliffe LM. Evaluation of sonographic renal parenchymal area in the management of hydronephrosis. *J Urol* 2001;165:548-51.
  59. Szymanski KM, Al-Said AN, Pippi Salle JL, Capolicchio JP. Do infants with mild prenatal hydronephrosis benefit from screening for vesicoureteral reflux? *J Urol* 2012;188:576-81.
  60. Tombesi MM, Alconcher LF. Short-term outcome of mild isolated antenatal hydronephrosis conservatively managed. *J Pediatr Urol* 2012;8:129-33.
  61. Lee JH, Choi HS, Kim JK, Won HS, Kim KS, Moon DH, et al. Nonrefluxing neonatal hydronephrosis and the risk of urinary tract infection.

- J Urol 2008;179:1524-8.
62. Yavascan O, Aksu N, Anil M, Kara OD, Aydin Y, Kangin M, et al. Post-natal assessment of growth, nutrition, and urinary tract infections of infants with antenatally detected hydronephrosis. *Int Urol Nephrol* 2010;42:781-8.
  63. Lidelfelt KJ, Herthelius M. Antenatal hydronephrosis: infants with minor postnatal dilatation do not need prophylaxis. *Pediatr Nephrol* 2008;23:2021-4.
  64. Braga LH, Mijovic H, Farrokhyar F, Pemberton J, DeMaria J, Lorenzo AJ. Antibiotic prophylaxis for urinary tract infections in antenatal hydronephrosis. *Pediatrics* 2013;131:e251-61.
  65. Braga LH, Easterbrook B, Jegatheeswaran K, Lorenzo AJ. From research question to conducting a randomized controlled trial on continuous antibiotic prophylaxis in prenatal hydronephrosis: a rational stepwise process. *Front Pediatr* 2016;4:27.
  66. Estrada CR, Peters CA, Retik AB, Nguyen HT. Vesicoureteral reflux and urinary tract infection in children with a history of prenatal hydronephrosis: should voiding cystourethrography be performed in cases of postnatally persistent grade II hydronephrosis? *J Urol* 2009;181:801-7.
  67. Merguerian PA, Herz D, McQuiston L, Van Bibber M. Variation among pediatric urologists and across 2 continents in antibiotic prophylaxis and evaluation for prenatally detected hydronephrosis: a survey of American and European pediatric urologists. *J Urol* 2010;184(4 Suppl):1710-5.
  68. Silay MS, Undre S, Nambiar AK, Dogan HS, Kocvara R, Nijman RJ, et al. Role of antibiotic prophylaxis in antenatal hydronephrosis: a systematic review from the European Association of Urology/European Society for Paediatric Urology Guidelines Panel. *J Pediatr Urol* 2017;13:306-15.